Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Amyotrophic Lateral Sclerosis
RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis
Status | Recruiting |
Enrollment | 40 |
Est. completion date | September 30, 2022 |
Est. primary completion date | August 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Male or female subject with age 20 years to 75 years at the time of signed consent 2. Patients who are defined as "definite ALS," "probable ALS" or "probable-laboratory-supported ALS," met diagnostic criteria revised EL Escorial for Airlie House. 3. ALSFRS-R > 20 4. Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life 5. Patients of less than 3 years after the onset of ALS 6. Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend) 7. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation Exclusion Criteria: 1. Received treatment with other experimental therapies within the last 30 days prior to the first dose 2. Previously received treatment with RT001 3. Refusal to discontinue fish oils or other oil-based supplements for the duration of the study (Screening till last study procedure completed) 4. SVC < 70 at screening 5. Subject has a feeding tube or the need for a feeding tube is anticipated within the first 24 weeks after enrollment 6. Subject resides at a skilled nursing or dementia care facility, or admission to such a facility is planned during the study period 7. Evidence of any clinically significant neurological disorder other than ALS 8. The subject has a history of or currently has schizophrenia, schizoaffective disorder or bipolar disorder according to DSM-V or ICD-10 criteria 9. The subject has a significant pulmonary disorder not attributed to ALS or who require treatments that might complicate the evaluation of the effect of ALS on respiratory function 10. Subject has had a significant illness or infection requiring medical intervention in the past 30 days 11. Female who is breastfeeding or has a positive pregnancy test 12. Male participant or female participant of childbearing potential, who is sexually active and unwilling/unable to use a medically acceptable and effective double barrier birth control method throughout the study 13. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to return for visits as scheduled 14. History, within the last 2 years, of alcohol abuse or physical opioid dependence |
Country | Name | City | State |
---|---|---|---|
Estonia | University of Tartu | Tartu | |
Latvia | Riga Stradins Universtiy | Riga | |
Netherlands | UMC Utrecht | Utrecht | |
Sweden | Karolinska | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Retrotope, Inc. |
Estonia, Latvia, Netherlands, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in the revised ALS Functional Rating Score (ALSFRS-R) at 24 weeks | Change from baseline in ALSFRS-R will be compared for the RT001 treated group vs placebo | 24 weeks | |
Secondary | Composite of Death or a Specified State of Disease Progression | Change from baseline in the composite endpoint will be compared for the RT001 treated group vs placebo | 24 weeks | |
Secondary | Change from Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) | Change from baseline in ALSAQ40 will be compared for the RT001 treated group vs placebo | 24 weeks | |
Secondary | Change from baseline in SVC | Change from baseline in SVC will be compared for the RT001 treated group vs placebo | 24 weeks | |
Secondary | Frequency, severity and relationship to study drug of AEs and SAEs | Frequency, severity and relationship to study drug of AEs and SAEs will be compared for the RT001 treated group vs placebo | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |